[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 110
1. Spugnini EP, Dotsinsky I, Mudrov N, De Luca A, Codini C, Citro G, D'Avino A, Baldi A: Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy). In Vivo; 2008 Jan-Feb;22(1):51-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy).
  • Canine apocrine gland carcinoma is a locally aggressive neoplasm that can occasionally lead to metastatic spread, thus mimicking the behavior of their human counterpart.
  • Electrochemotherapy is a safe and efficacious therapy for metastatic carcinoma and warrants further investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apocrine Glands / pathology. Carcinoma / veterinary. Electrochemotherapy / veterinary. Mitoxantrone / therapeutic use. Sweat Gland Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396782.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


2. Francisco JS, Alfaro SE, Oliveira DC, Tonon S, Dias EP: Apocrine carcinoma in the parotid gland and in the submandibular region. Braz J Otorhinolaryngol; 2005 Mar-Apr;71(2):224-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma in the parotid gland and in the submandibular region.
  • The objectives of this paper are to report a case of apocrine carcinoma and the discussion of aspects related to its diagnosis, treatment, and prognosis.
  • Carcinomas with apocrine differentiation not related to extramammary Paget's disease, ductal breast carcinoma, Moll's glands adenocarcinoma and ceruminous glands carcinoma are very uncommon tumors.
  • We report a case of a 51-year-old black woman who developed apocrine carcinoma lesions in the head and neck region.
  • Two lesions involved her left parotid gland (first tumor and local recurrence), and other involved her submandibular skin.
  • Based on cutaneous apocrine carcinoma compatibility of the microscopic aspects, we concluded that the tumor in the submandibular skin was probably the primary neoplasm.
  • [MeSH-major] Apocrine Glands. Carcinoma / pathology. Mouth Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446921.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Miyamoto T, Hagari Y, Inoue S, Watanabe T, Yoshino T: Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature. J Clin Pathol; 2005 Jul;58(7):757-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature.
  • BACKGROUND: Apocrine carcinoma is rare and often occurs in the axilla.
  • This is the second apocrine carcinoma arising in bilateral axillae with associated apocrine hyperplasia to be reported.
  • AIMS/METHODS: Because benign apocrine tumours may be precursors of cancer, this case was investigated immunohistochemically and histologically, and a literature (English and Japanese) review undertaken of cases with coexistent malignant and benign apocrine tumours in the axilla to elucidate the relation between apocrine carcinoma and benign apocrine tumours.
  • RESULTS: Only four cases of axillary apocrine carcinoma with benign apocrine tumours were identified in the literature.
  • In each case, benign apocrine hyperplasia was situated within and surrounding the adenocarcinomatous nests.
  • (2) combined luminal surface and cytoplasmic staining of glandular cells; and (3) a strongly positive lineal staining pattern at the luminal membrane surface, comprising one or two apocrine hyperplastic secretory cells.
  • The basal lesions of apocrine hyperplasia were strongly positive for alpha smooth muscle actin, whereas the periphery of adenomatous lesions showed weaker positive staining, even though the periphery of adenocarcinomatous lesions was negative.
  • CONCLUSIONS: All five apocrine carcinomas with benign apocrine tumours occurred in elderly Japanese men who had bilateral benign apocrine tumours even if affected by unilateral axillary apocrine carcinoma.
  • The immunohistochemical results support the notion that apocrine hyperplasia is a precursor of cancer and that apocrine carcinoma, adenoma, and hyperplasia may be successive steps in the linear progression to carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Apocrine Glands / pathology. Precancerous Conditions / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Sweat Gland / pathology. Aged. Aged, 80 and over. Axilla. Humans. Hyperplasia. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):131-5 [10199445.001]
  • [Cites] J Dermatol. 1997 Aug;24(8):535-8 [9301148.001]
  • [Cites] Pathol Res Pract. 2001;197(6):419-25 [11432669.001]
  • [Cites] Pathol Int. 2002 Feb;52(2):169-73 [11940224.001]
  • [Cites] J Pathol. 2002 Dec;198(4):458-67 [12434415.001]
  • [Cites] J Pathol. 2003 Jan;199(1):1-3 [12474219.001]
  • [Cites] J Dermatol. 2003 Jan;30(1):72-5 [12598714.001]
  • [Cites] Histopathology. 1989 Apr;14(4):409-16 [2544501.001]
  • [Cites] Acta Pathol Jpn. 1990 Jun;40(6):431-4 [2203231.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):927-32 [1785351.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Dermatopathol. 2001 Feb;23(1):50-7 [11176053.001]
  • (PMID = 15976347.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC1770727
  •  go-up   go-down


Advertisement
4. Usui K, Ochiai T, Abe I, Nishio H, Togo K, Yamagata M: Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon. J Dermatol; 2010 Apr;37(4):350-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon.
  • We reported a 52-year-old woman with an apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon.
  • Our diagnosis revealed that the nodule was an apocrine gland carcinoma and the intraepidermal neoplastic cells with pagetoid spread in the pigmented plaque were derived from the apocrine gland carcinoma.
  • No Paget's cells were detected in the right nipple, and no tumor cells were observed in the sentinel lymph node and underlying mammary gland tissue.
  • They showed that both intraepidermal neoplastic cells with pagetoid spread and tumor cells of the apocrine gland carcinoma were positive with cytokeratin-7 and human epidermal growth factor receptor-2 (HER-2)/neu overexpression.
  • The results of the present study conclude that the intraepithelial spread of tumor cells in the mammary skin distant from the nipple occurred as a pagetoid phenomenon, and that HER-2 may have a key role in pagetoid phenomenon of an underlying apocrine gland carcinoma, as well as in mammary Paget's disease.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Paget's Disease, Mammary / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507405.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-7; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


5. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z: EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol; 2010 May;23(5):644-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.
  • This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology.
  • In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17.
  • On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile.
  • Her-2/neu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas).
  • HER-2/neu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas).
  • EGFR protein (scores 1 to 3+) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P=0.006).
  • In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P=0.006, r=-0.499).
  • EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma.
  • Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P=0.083) and showed a weak positive correlation with EGFR protein expression (P=0.025, r=0.326).
  • Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas.
  • Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype.
  • Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208479.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Steroid; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


6. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol; 2007 Sep;34(9):693-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our routine practice, we observed that CD23 reacted strongly with eccrine and apocrine secretory coils.
  • METHODS: Immunohistochemical staining of CD23 was performed in a total of 131 cases of apocrine, eccrine, follicular and other cutaneous non-lymphoid tumors.
  • RESULTS: CD23 expression was detected in all benign apocrine tumors and in half of benign eccrine tumors, particularly those derived from secretory coils.
  • CD23 staining was seen in 42% (8/19) of microcystic adnexal carcinoma (MAC), while no staining was observed in tumor cells of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma and syringoma.
  • In comparison, pagetoid Bowen's disease, melanoma in situ and sebaceous carcinoma exhibited negative staining.
  • In addition, CD23 reacted diffusely with cutaneous mucinous eccrine carcinoma in a manner similar to breast or colonic adenocarcinoma.
  • CONCLUSION: CD23 appears to be a reliable immunohistochemical marker of the eccrine/apocrine secretory coil and helpful in identifying sweat gland tumors of such origin.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Receptors, IgE / metabolism. Sweat Gland Neoplasms / metabolism
  • [MeSH-minor] Apocrine Glands / metabolism. Apocrine Glands / pathology. Eccrine Glands / metabolism. Eccrine Glands / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696916.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


7. Crain N, Nelson BL, Barnes EL, Thompson LD: Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases. Head Neck Pathol; 2009 Mar;3(1):1-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ceruminous gland carcinomas: a clinicopathologic and immunophenotypic study of 17 cases.
  • BACKGROUND: Ceruminal gland carcinomas are rare neoplasms confined to the skin lining the cartilaginous part of the external auditory canal.
  • Metastatic adenocarcinoma or direct extension from salivary gland neoplasms are the principle differential considerations.
  • CONCLUSION: Ceruminous-type carcinomas, with the exception of ceruminous mucoepidermoid carcinoma, all demonstrated a dual cell population of basal myoepithelial-type cells and luminal apocrine cells.
  • [MeSH-major] Carcinoma / pathology. Ear Neoplasms / pathology. Ear, External / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1973 Jun;65(6):909-13 [4350087.001]
  • [Cites] J Laryngol Otol. 1973 Dec;87(12):1201-10 [4357381.001]
  • [Cites] J Laryngol Otol. 1974 Apr;88(4):363-8 [4824672.001]
  • [Cites] Can J Otolaryngol. 1974;3(2):194-201 [4831936.001]
  • [Cites] Arch Otolaryngol. 1974 Nov;100(5):395-7 [4429488.001]
  • [Cites] Cancer. 1975 Sep;36(3):1072-6 [171051.001]
  • [Cites] J Laryngol Otol. 1975 Jul;89(7):707-20 [171328.001]
  • [Cites] Arch Otolaryngol. 1975 Nov;101(11):702-5 [1200915.001]
  • [Cites] Laryngoscope. 1977 Oct;87(10 Pt 1):1601-12 [198620.001]
  • [Cites] J Can Assoc Radiol. 1977 Dec;28(4):287-90 [303644.001]
  • [Cites] Cancer. 1978 Feb;41(2):545-53 [630537.001]
  • [Cites] Arch Otolaryngol. 1980 Jan;106(1):13-9 [6243462.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Dec;30(13):1034-7 [1714051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):214-5 [1310808.001]
  • [Cites] Acta Morphol Hung. 1991;39(2):157-65 [1789146.001]
  • [Cites] J Laryngol Otol. 1992 Aug;106(8):727-32 [1328435.001]
  • [Cites] Pathology. 1992 Oct;24(4):315-9 [1337771.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1993;114(1):49-52 [8191051.001]
  • [Cites] J Laryngol Otol. 1994 Aug;108(8):706-9 [7930929.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2873-83 [6291744.001]
  • [Cites] J Laryngol Otol. 1995 Mar;109(3):180-8 [7745330.001]
  • [Cites] Am J Dermatopathol. 1995 Apr;17(2):169-73 [8600783.001]
  • [Cites] J Laryngol Otol. 1996 Mar;110(3):249-51 [8730361.001]
  • [Cites] J Am Anim Hosp Assoc. 1996 Sep-Oct;32(5):448-52 [8875362.001]
  • [Cites] Indian J Cancer. 1997 Sep;34(3):139-42 [9491676.001]
  • [Cites] Br J Plast Surg. 1998 Jun;51(4):317-20 [9771352.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):824-31 [13491925.001]
  • [Cites] J Laryngol Otol. 1957 Dec;71(12):832-7 [13491926.001]
  • [Cites] Cancer. 1964 Jan;17:67-75 [14102073.001]
  • [Cites] J Otolaryngol. 1980 Dec;9(6):482-6 [6162967.001]
  • [Cites] J Laryngol Otol. 1981 Aug;95(8):843-8 [6267150.001]
  • [Cites] J Neurosurg. 1981 Dec;55(6):952-6 [7299469.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):153-61 [7039299.001]
  • [Cites] Laryngoscope. 1983 Mar;93(3):326-40 [6300574.001]
  • [Cites] Hiroshima J Med Sci. 1984 Mar;33(1):17-22 [6090347.001]
  • [Cites] J Am Acad Dermatol. 1984 Nov;11(5 Pt 1):841-7 [6096419.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] Am J Otol. 1987 Nov;8(6):485-8 [3434612.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2292-302 [2804921.001]
  • [Cites] J R Soc Med. 1990 Jan;83(1):34-7 [2406442.001]
  • [Cites] J Laryngol Otol. 1999 Jun;113(6):578-80 [10605594.001]
  • [Cites] J Otolaryngol. 2001 Dec;30(6):373-7 [11771014.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):87-9 [11800656.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Apr;60(4):465-9 [11928113.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):834-7 [12117346.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Sep-Oct;64(5):358-63 [12417781.001]
  • [Cites] J Laryngol Otol. 2003 Mar;117(3):202-4 [12648377.001]
  • [Cites] Am J Otolaryngol. 2003 Jul-Aug;24(4):274-7 [12884224.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Dec;24(6):354-6 [15952686.001]
  • [Cites] Ear Nose Throat J. 2005 Sep;84(9):560-1 [16261754.001]
  • [Cites] Otol Neurotol. 2006 Jan;27(1):97-101 [16371854.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Oct;49(4):587-9 [17183866.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):280-4 [17364365.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Dec;137(6):893-8 [18036417.001]
  • [Cites] J Neurosurg. 2008 Jan;108(1):97-104 [18173317.001]
  • [Cites] B-ENT. 2007;3(4):195-9 [18265725.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):663-6 [18559737.001]
  • [Cites] Laryngoscope. 2008 Sep;118(9):1591-6 [18677277.001]
  • [Cites] Auris Nasus Larynx. 2003 Aug;30(3):287-90 [12927294.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):792-4 [14526681.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Sep-Oct;65(5):300-2 [14730188.001]
  • [Cites] J Laryngol Otol. 2003 Dec;117(12):951-4 [14738604.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):308-18 [15104293.001]
  • [Cites] Arch Otolaryngol. 1967 Jul;86(1):66-9 [6026961.001]
  • [Cites] Arch Dermatol. 1968 Oct;98(4):344-8 [4300211.001]
  • [Cites] Arch Otolaryngol. 1970 Jul;92(1):40-2 [4192890.001]
  • [Cites] J Laryngol Otol. 1970 Jul;84(7):743-5 [5432829.001]
  • [Cites] Pract Otorhinolaryngol (Basel). 1970;32(4):211-8 [5477506.001]
  • [Cites] Cancer. 1971 Sep;28(3):775-80 [4328926.001]
  • [Cites] Tex Med. 1970 Oct;66(10):56-9 [4335213.001]
  • [Cites] Cancer. 1972 May;29(5):1169-78 [5021609.001]
  • (PMID = 20596983.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807538
  • [Keywords] NOTNLM ; Adenoid cystic / Carcinoma / Ceruminal / Ceruminous / Ear / Gland / Immunohistochemistry / Mucoepidermoid / Prognosis
  •  go-up   go-down


8. Guerriero S, Ruffolo C, Lombardi AR, Tirone A, Tirone G: Recurrent pleural effusion and pulmonary metastases from a cutaneous apocrine tumour of the axilla. Acta Chir Belg; 2007 Nov-Dec;107(6):697-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pleural effusion and pulmonary metastases from a cutaneous apocrine tumour of the axilla.
  • Sweat gland carcinomas are very rare and they are differentiated between tumours of apocrine or eccrine origin.
  • The axilla is the most common site for apocrine gland carcinoma for its great abundance of these glands.
  • There are no recommendations in literature regarding appropriate treatment schedules for apocrine gland carcimonas in advanced stages.
  • We report a case of recurrent left pleural effusion in a 76-year old man with metastatic cutaneous apocrine tumour of the right axilla.
  • We describe the clinical and histological features, with management options and a review of the relevant literature on apocrine gland carcinoma.
  • [MeSH-major] Apocrine Glands. Axilla. Lung Neoplasms / secondary. Pleural Effusion / etiology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / complications. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274189.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


9. Roy S, Shafi NQ, Rose MG: Locally recurrent and metastatic apocrine-gland carcinoma in an elderly man. Nat Clin Pract Oncol; 2007 Jan;4(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally recurrent and metastatic apocrine-gland carcinoma in an elderly man.
  • DIAGNOSIS: Carcinoma of the axillary apocrine gland.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183356.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Maury G, Guillot B, Bessis D, Cribier B, Girard C: [Unusual axillary apocrine carcinoma of the skin: histological diagnostic difficulties]. Ann Dermatol Venereol; 2010 Aug-Sep;137(8-9):555-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual axillary apocrine carcinoma of the skin: histological diagnostic difficulties].
  • [Transliterated title] Carcinome apocrine cutané axillaire inhabituel : difficultés diagnostiques histologiques.
  • BACKGROUND: Apocrine carcinoma of the skin (ACS) is a rare adnexal neoplasm presenting as an indurated slow-growing dermal or subcutaneous plaque that often occurs in the axilla.
  • Histological distinction between ACS and cutaneous metastases of breast carcinoma may be difficult.
  • The pattern of the tumour and immunohistochemical staining suggested a diagnosis of breast carcinoma metastasis.
  • The differential diagnostic between axillary ACS and metastasis of lobular breast carcinoma has been discussed recently.
  • CONCLUSION: We report a new case of axillary ACS histologically mimicking lobular breast carcinoma metastasis.
  • [MeSH-major] Carcinoma / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Axilla. Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / secondary. Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20804902.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


11. Misago N, Ohkawa T, Narisawa Y: An unusual apocrine carcinoma on the forehead. Am J Dermatopathol; 2007 Aug;29(4):404-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual apocrine carcinoma on the forehead.
  • We herein report an unusual case of apocrine carcinoma on the forehead.
  • The lesion was formed by the anastomosis of numerous tubular structures with widespread decapitation secretion, thus demonstrating apocrine differentiation.
  • However, we observed some unusual histopathologic features that differed from those found in typical examples of apocrine ductal carcinoma, namely:.
  • We believe the present case is an apocrine ductal carcinoma, although it has a nodular appearance and basaloid cells.
  • Otherwise, it could be a hitherto undescribed variant of apocrine carcinoma.
  • This apocrine carcinoma on the forehead may have originated from either pluripotential cells or from apocrine glands at an unusual site.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Ductal / pathology. Forehead / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667178.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Keratin-19; 0 / Keratin-7; 0 / Mucin-1; 0 / PIP protein, human; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


12. Miyamoto T, Adachi K, Fujishima M: Axillary apocrine carcinoma with Paget's disease and apocrine naevus. Clin Exp Dermatol; 2009 Jul;34(5):e110-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with Paget's disease and apocrine naevus.
  • Apocrine carcinoma is a rare malignant sweat-gland neoplasm with apocrine differentiation.
  • There have been some reported cases of apocrine carcinoma with apocrine naevus.
  • The resected specimen showed apocrine adenocarcinoma with extramammary Paget's disease and apocrine naevus.
  • On resection of this enlarging right axilla, an apocrine naevus was found.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Nevus / diagnosis. Paget Disease, Extramammary / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Apocrine Glands. Axilla. Humans. Male. Positron-Emission Tomography. Precancerous Conditions / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438526.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Miyamoto T, Inoue S, Adachi K, Takada R: Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease and apocrine nevus. J Cutan Pathol; 2009 May;36(5):529-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease and apocrine nevus.
  • BACKGROUND: Apocrine carcinomas are rare, the immunohistochemical characterizations that are incomplete.
  • The purpose of this study was to determine the immunohistochemical characteristics of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease (EMPD) and apocrine nevus.
  • METHODS: We report four cases of apocrine carcinomas along with immunohistochemical analyses: (i) an axillary apocrine carcinoma with an apocrine nevus, (ii) an inguinal apocrine carcinoma, (iii) a vulvar apocrine carcinoma with EMPD and (iv) an axillary apocrine carcinoma with EMPD and an apocrine nevus.
  • RESULTS: The tumor cells of apocrine carcinomas, EMPD and apocrine nevi displayed a positive reaction to MUC-1 and CK7 and a negative reaction to CK20.
  • Apocrine carcinomas had high molecular weight (HMW) cytokeratin(+)/CK5(+)/CK14(-)/MUC5AC(-), EMPD with underlying apocrine carcinoma had HMW cytokeratin(-)/CK5(-)/CK14(-)/MUCA5AC(-) and the apocrine nevi had HMW cytokeratin(+)/CK5(+)/CK14(+)/MUCA5AC(+).
  • CONCLUSION: The immunohistochemical findings suggest that apocrine carcinomas, apocrine nevi and EMPD with underlying apocrine carcinomas are quite different, even though they are all derived from apocrine glands.
  • [MeSH-major] Carcinoma, Skin Appendage / metabolism. Keratins / biosynthesis. Mucins / biosynthesis. Nevus / metabolism. Paget Disease, Extramammary / metabolism. Sweat Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476520.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


14. Bujas T, Pavić I, Lenicek T, Mijić A, Kruslin B, Tomas D: Axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia. Acta Dermatovenerol Croat; 2007;15(3):148-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia.
  • Apocrine carcinomas represent a rare group of tumors with a potential for destructive local invasion, regional and distant metastases, and are equally common in both sexes.
  • A case of a 79-year-old woman with axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia is presented.
  • The cells contained abundant eosinophilic, finely granular cytoplasm with pleomorphic nuclei and showed apocrine-like decapitation.
  • In one area, the tumor was lobular and composed of tubular structures lined with one layer of uniform cuboidal or columnar eosinophilic cells, indicating a pre-existing apocrine adenoma.
  • Beneath the tumor, in the deep dermis and subcutaneous tissue, hyperplastic apocrine glands were also found.
  • This and previously reported cases suggest that apocrine hyperplasia and apocrine adenoma may represent successive steps in the development of apocrine carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868540.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


15. Robson A, Lazar AJ, Ben Nagi J, Hanby A, Grayson W, Feinmesser M, Granter SR, Seed P, Warneke CL, McKee PH, Calonje E: Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol; 2008 May;32(5):682-90
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases.
  • Primary cutaneous apocrine carcinoma is a rare malignancy.
  • This study of 24 examples suggests that the prognosis is not always poor and that grading criteria devised for breast carcinoma may have utility in this group of malignancies.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2009 Jan;33(1):155-7 [18971780.001]
  • (PMID = 18347508.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Somasundaram SK, Balasubramanian RK, Aref F, Karim S, Vashisht R: A rare and unusual case of bilateral, axillary, metachronous apocrine carcinoma. Int Surg; 2007 Nov-Dec;92(6):335-8
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare and unusual case of bilateral, axillary, metachronous apocrine carcinoma.
  • Apocrine carcinoma is a rare sweat gland neoplasm with very few cases reported in the published literature.
  • We report a case of primary axillary apocrine carcinoma with later recurrences in both axillae.
  • [MeSH-major] Adenocarcinoma / secondary. Apocrine Glands / pathology. Breast Neoplasms, Male / pathology. Neoplasms, Second Primary. Sweat Gland Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402127.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Zelger BG, Stelzmueller I, Dunst KM, Zelger B: Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma. J Cutan Pathol; 2008 Mar;35(3):332-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma.
  • The so called 'sweat gland carcinoma' is a rare skin malignancy.
  • The differentiation between apocrine and eccrine neoplasms remains difficult.
  • A 71-year-old man presented with a morphea-like plaque of the right axilla which in punch biopsy was first suspected as metastasis of primary lobular breast carcinoma.
  • After further clinical and laboratory work up including immunohistochemistry the original diagnosis of a breast cancer had to be changed to solid apocrine carcinoma of the skin.
  • Solid apocrine carcinoma of the skin is a rare variant with apocrine differentiation.
  • A survey of the stereotypical presentation of this lesion and a comparison with lobular breast carcinoma and other types of apocrine carcinoma of the skin is given.
  • [MeSH-major] Adenocarcinoma / diagnosis. Apocrine Glands / pathology. Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251751.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Hernandez JM, Copeland EM 3rd: Infiltrating apocrine adenocarcinoma with extramammary pagetoid spread. Am Surg; 2007 Mar;73(3):307-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating apocrine adenocarcinoma with extramammary pagetoid spread.
  • Apocrine adenocarcinoma is a rare malignancy with invasive potential.
  • We report on a case of apocrine carcinoma presenting with lymph node infiltration and extensive extramammary Paget's disease.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375797.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Treiyer A, Haben B, Röttger P, Steffens J: First male apocrine genital carcinoma mimicking a penile cancer. Urology; 2008 Mar;71(3):546.e11-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First male apocrine genital carcinoma mimicking a penile cancer.
  • Perineal apocrine carcinoma is a rare malignant tumor that has its origin in the apocrine sudoriparous glands of the genital and perianal regions.
  • We report a case of a genital apocrine carcinoma located at the penile basis.
  • To our knowledge our report represents the first case of a pathologically confirmed genital apocrine carcinoma mimicking a penile cancer.
  • [MeSH-major] Apocrine Glands. Penile Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342207.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fernandez-Flores A: Mammaglobin immunostaining in the differential diagnosis between cutaneous apocrine carcinoma and cutaneous metastasis from breast carcinoma. Cesk Patol; 2009 Oct;45(4):108-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin immunostaining in the differential diagnosis between cutaneous apocrine carcinoma and cutaneous metastasis from breast carcinoma.
  • The differential diagnosis between cutaneous apocrine carcinoma (CAC) and cutaneous metastases from breast carcinoma is commonly difficult.
  • We used the antibody mammaglobin in order to study 10 cases of cutaneous metastasis of ductal breast carcinoma, and 2 cases of CAC.
  • Four cases of metastatic breast carcinoma also showed scattered positive cells.
  • One case of metastatic breast carcinoma did not show any expression of mammaglobin at all.
  • [MeSH-major] Apocrine Glands. Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Neoplasm Proteins / analysis. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / secondary. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20301838.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


21. Akhtar I, Ispas CL, Flowers R, Siddiqi A, Young L, Donnellan KA, Heard K, Baliga M: Ductopapillary apocrine carcinoma of the eyelid metastatic to the parotid gland: report of a case diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol; 2009 Feb;37(2):91-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductopapillary apocrine carcinoma of the eyelid metastatic to the parotid gland: report of a case diagnosed by fine-needle aspiration biopsy.
  • Ductopapillary apocrine carcinoma (DPAC) of the eyelid is a rare malignant neoplasm in the periocular region.
  • We report a case of a 65-year-old African-American male with a history of ductopapillary apocrine adenocarcinoma of the eyelid, diagnosed 6 weeks ago now presenting with a recurrence in the same area.
  • FNAB of the parotid mass showed a well-differentiated papillary adenocarcinoma with a cystic component, similar to a previously excised ductopapillary apocrine adenocarcinoma of the eyelid.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Eyelid Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Parotid Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021198.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  •  go-up   go-down


22. Shim HS, Jung WH, Kim H, Park K, Cho NH: Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS; 2006 May;114(5):352-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
  • We investigated the role of these hormones in breast apocrine lesions (BAL) using immunohistochemistry to study androgen receptors (AR) and the inhibin/activin alpha and betaA subunits.
  • Forty-two cases of BAL were evaluated, including 22 cases of fibrocystic disease (FCD) showing prominent apocrine changes, 10 intraductal papillomas with extensive apocrine metaplasia, 5 cases of apocrine carcinoma in situ (CIS), and 5 cases of apocrine carcinoma.
  • Fifty non-apocrine lesions were included as controls: 20 cases of FCD, 5 cases of DCIS, and 25 cases of invasive ductal carcinoma.
  • AR was more frequently expressed in BAL than in non-apocrine lesions (p=0.001).
  • As the expression of the alpha and betaA subunits reflects inhibin and activin A, respectively, AR and activin A may be implicated in apocrine morphogenesis, but not in tumor progression.
  • [MeSH-major] Apocrine Glands / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Fibrocystic Breast Disease / metabolism. Inhibin-beta Subunits / metabolism. Inhibins / metabolism. Metaplasia / metabolism. Papilloma, Intraductal / metabolism. Receptors, Androgen / metabolism. Sweat Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725011.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


23. Pai RR, Kini JR, Achar C, Rau A, Kini H: Apocrine (cutaneous) sweat gland carcinoma of axilla with signet ring cells: a diagnostic dilemma on fine-needle aspiration cytology. Diagn Cytopathol; 2008 Oct;36(10):739-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine (cutaneous) sweat gland carcinoma of axilla with signet ring cells: a diagnostic dilemma on fine-needle aspiration cytology.
  • Carcinoma arising in the apocrine sweat glands is rare and there are few reports describing the cytological features of this neoplasm.
  • We describe the cytological features of a histologically confirmed apocrine carcinoma occurring in a 55-year-old man who presented with an ulcerated mass in the right axilla.
  • In an axillary mass lesion, cytological features along with clinical correlation are essential to distinguish primary apocrine carcinoma from mammary neoplasms with signet ring cells and other metastatic adenocarcinomas.
  • [MeSH-major] Axilla. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773442.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kaya H, Bozkurt SU, Erbarut I, Djamgoz MB: Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract; 2008;204(6):367-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
  • The aims of this study were twofold: (i) to determine the occurrence frequency of apocrine carcinoma of the breast (ApBCa) in Turkish breast cancer (BCa) patients; and (ii) to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), gross cystic disease protein-15 (GCDFP-15), c-erbB-2, and p53 in these cases.
  • The results of ApBCa were compared with those of invasive ductal carcinoma not otherwise specified type (IDC-NOS) cases of similar grade.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism. Sweat Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Apocrine Glands / metabolism. Apocrine Glands / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carrier Proteins / metabolism. Female. Glycoproteins / metabolism. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342452.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / Receptors, Steroid; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


25. Bezić J, Forempoher G, Poljicanin A, Gunjaca G: Apocrine adenoma of the breast coexistent with invasive carcinoma. Pathol Res Pract; 2007;203(11):809-12
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast coexistent with invasive carcinoma.
  • We describe a case of apocrine adenoma with simultaneous occurrence of invasive ductal carcinoma in the breast of a 53-year-old woman.
  • Apocrine adenoma affecting the breast is very rare.
  • The lesion is composed of back-to-back ducts and papillary fronds covered with apocrine cells, and it is sharply demarcated from the surrounding breast tissue.
  • The ultrasound also revealed in the surrounding breast parenchyma an additional abnormal finding suggestive of carcinoma.
  • Histologic examination of the excised specimen showed that the hypoechogenic nodule represented an apocrine adenoma in proximity to the invasive ductal breast carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Multiple Primary / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936522.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


26. Seethala RR, Richmond JA, Hoschar AP, Barnes EL: New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine. Arch Pathol Lab Med; 2009 Jun;133(6):950-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine.
  • CONTEXT: Recently described variants of epithelial-myoepithelial carcinoma have not been well characterized but raise a distinct set of differential diagnostic considerations than the classic type.
  • OBJECTIVE: To report a detailed analysis of oncocytic-sebaceous epithelial-myoepithelial carcinoma (OEMCa) and a similar, but novel, variant, apocrine epithelial-myoepithelial carcinoma (ApEMCa).
  • CONCLUSIONS: Oncocytic-sebaceous epithelial-myoepithelial carcinoma and ApEMCa should be considered in the differential diagnosis of oncocytic/oncocytoid salivary gland tumors.
  • Oncocytic-sebaceous epithelial-myoepithelial carcinoma morphology may reflect a senescent phenotype, similar to other oncocytic lesions.
  • The ductal component of ApEMCa shares some similarities with salivary duct carcinoma and supports the notion that epithelial-myoepithelial carcinoma can serve as the progenitor tumor for hybrid tumors.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Apocrine Glands / pathology. Carcinoma / pathology. Myoepithelioma / pathology. Parotid Neoplasms / pathology


27. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordoñez B: Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am J Surg Pathol; 2006 Aug;30(8):1014-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation.
  • Low-grade intraductal carcinomas (LG-IDCs) of salivary gland are rare neoplasms that resemble atypical ductal hyperplasia or LG-IDCs of the breast.
  • Herein, we describe 3 additional cases of LG-IDCs, 2 were pure intraductal carcinomas, although 1 demonstrated increasing cytologic atypia and progression to an invasive adenosquamous carcinoma.
  • The intraductal component in all cases exhibited a remarkable degree of apocrine differentiation.
  • Extensive apocrine differentiation, expression of ARs, CK7, and CK19, and progression to a widely invasive carcinoma after a long clinical latency have not been reported in LG-IDCs previously.
  • These tumors share some histopathologic features with salivary duct carcinoma including apocrine differentiation, and expression of ARs and BRST-2.
  • The terms "low-grade salivary duct carcinomas" and "low-grade cribriform cystadenocarcinomas" should be abandoned in favor of LG-IDC of salivary gland, which better reflects their predominantly noninvasive, intraductal nature.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861974.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Kazakov DV, Kutzner H, Spagnolo DV, Kempf W, Zelger B, Mukensnabl P, Michal M: Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). Am J Dermatopathol; 2008 Feb;30(1):21-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma).
  • We describe 11 poroid neoplasms with sebaceous differentiation, including a metaplastic (sarcomatoid) carcinoma arising in association with an apocrine poroma.
  • The single carcinoma was an ulcerated oval to spindle cell neoplasm surrounded laterally by the residuum of a poroma containing groups of sebocytes.
  • The epithelial islands of the poroma were prominently keratinized and blended gradually with the pleomorphic cells of the metaplastic carcinoma that immunohistochemically stained focally for cytokeratins and simultaneously showed strong vimentin expression.
  • Occurrence of metaplastic carcinoma in association with apocrine poroma is a rare event which indicates the existence of a malignant counterpart of the latter entity, which can be descriptively referred to as "sarcomatoid apocrine porocarcinoma. "
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212539.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Simeonov RS, Simeonova GP: Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears. J Vet Med A Physiol Pathol Clin Med; 2007 Nov;54(9):542-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears.
  • The results indicated an increase in the mean values of investigated parameters from canine cutaneous apocrine adenomas (MNA, 75.65+/-2.22; MNP, 31.05+/-0.55; MND, 9.62+/-0.14; NR, 1.10+/-0.009) to canine cutaneous apocrine carcinomas (MNA, 88.78+/-11.29; MNP, 34.38+/-2.43; MND, 10.43+/-0.76; NR, 1.21+/-0.07).
  • The statistical differences between investigated parameters (P<0.01) were also found between the metastasizing apocrine carcinomas and all other examined carcinomas.
  • [MeSH-major] Adenoma / veterinary. Apocrine Glands / cytology. Carcinoma / veterinary. Cell Nucleus / pathology. Dog Diseases / pathology. Sweat Gland Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931233.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • Similar to vulvar lesions, peri-anal apocrine tumours are believed to arise in mammary like glands (MLGs).
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Wahl CE, Todd DH, Binder SW, Cassarino DS: Apocrine hidradenocarcinoma showing Paget's disease and mucinous metaplasia. J Cutan Pathol; 2009 May;36(5):582-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine hidradenocarcinoma showing Paget's disease and mucinous metaplasia.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Skin Appendage / pathology. Mucins / metabolism. Paget Disease, Extramammary / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Hidradenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476529.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-7; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


33. Shoieb AM, Hanshaw DM: Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007). Vet Pathol; 2009 Jul;46(4):677-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007).
  • A retrospective study was performed to characterize 64 cases of anal sac gland carcinoma (ASGC) in cats.
  • Apocrine gland origin was confirmed in a subset of these tumors by immunohistochemistry and the use of the glandular cytokeratin antibody (CAM 5.2).
  • Anal sac gland carcinoma accounted for 0.5% of all feline skin neoplasms.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Cat Diseases / epidemiology. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276061.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Hou JL, Wu LY, Zhang HT, Lv NN, Huang Y, Yu GZ: Clinicopathologic characteristics of 12 patients with vulvar sweat gland carcinoma. Int J Gynecol Cancer; 2010 Jul;20(5):874-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of 12 patients with vulvar sweat gland carcinoma.
  • OBJECTIVES: The aim of this article was to evaluate the clinical and pathologic characteristics, therapy, and prognostic factors of vulvar sweat gland carcinoma.
  • MATERIALS: Clinical and pathologic data for 12 patients with vulvar sweat gland carcinoma treated at our institution from January 1958 to April 2009 were retrospectively analyzed.
  • Of the 12 cases, 7 cases were vulvar sweat gland carcinoma, 3 cases were vulvar Paget disease with underlying sweat gland adenocarcinoma, 1 case was vulvar apocrine adenocarcinoma, and 1 case was adenoid cystic carcinoma of the vulvar sweat gland.
  • CONCLUSIONS: Vulvar sweat gland carcinoma is a very rare entity.
  • [MeSH-major] Sweat Gland Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606537.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Mahalingam M, Srivastava A, Hoang MP: Expression of stem-cell markers (cytokeratin 15 and nestin) in primary adnexal neoplasms-clues to etiopathogenesis. Am J Dermatopathol; 2010 Dec;32(8):774-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The overlap in histopathologic features and immunoprofile of eccrine and apocrine neoplasms confounds basic issues relating to lineage of these entities.
  • RESULTS: CK15 and nestin expression were noted in 39 of 78 (50%) and 36 of 78 (46%) cases in the benign group, respectively (8 cutaneous mixed tumor, 10 hidradenoma papilliferum, 9 apocrine cystadenoma, 11 cylindroma and/or spiradenoma, and 9 poroma/dermal duct tumor).
  • CK15 and nestin expression were noted in 11 of 23 (48%) and 7 of 23 (30%) cases in the malignant group, respectively (6 microcystic adnexal carcinoma, 7 porocarcinoma, and 9 eccrine carcinoma).
  • Except 1, both markers were negative in 4 syringocystadenoma papilliferum, 10 hidradenoma, 1 syringofibroadenoma, 10 syringoma, 1 eccrine adenoma, 8 poroma/dermal duct tumor, 5 eccrine hidrocystoma, and 1 apocrine carcinoma.
  • CONCLUSIONS: Given that follicular germinative cells give rise to the folliculosebaceous apocrine unit, expression of CK15 and nestin in the majority of cutaneous mixed tumor, hidradenoma papilliferum, apocrine cystadenoma, and cylindroma/spiradenoma is suggestive of an apocrine origin/differentiation of these neoplasms.
  • [MeSH-major] Apocrine Glands / chemistry. Biomarkers, Tumor / analysis. Eccrine Glands / chemistry. Intermediate Filament Proteins / analysis. Keratin-15 / analysis. Neoplasms, Adnexal and Skin Appendage / chemistry. Neoplastic Stem Cells / chemistry. Nerve Tissue Proteins / analysis. Sweat Gland Neoplasms / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700038.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT15 protein, human; 0 / Keratin-15; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


36. Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H: Loss of CYLD might be associated with development of salivary gland tumors. Oncol Rep; 2008 Jun;19(6):1421-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of CYLD might be associated with development of salivary gland tumors.
  • Molecular studies of cylindromas, which arise from the eccrine or apocrine cells of the skin, have demonstrated frequent alterations at chromosome 16q12-13, recently found to house the cylindromatosis (CYLD) gene.
  • We demonstrated previously that human salivary gland tumor (SGT) cell line, HSG spontaneously expresses CYLD and also found that adenoid cystic carcinoma (ACC) arising from the hard palate was distinctly positive for CYLD, immunohistochemically.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Genes, Tumor Suppressor / physiology. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497946.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Proteins; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


37. Etit D, Pilch BZ, Osgood R, Faquin WC: Fine-needle aspiration biopsy findings in sclerosing polycystic adenosis of the parotid gland. Diagn Cytopathol; 2007 Jul;35(7):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy findings in sclerosing polycystic adenosis of the parotid gland.
  • Sclerosing polycystic adenosis (SPA) is a recently described, rare lesion of the salivary gland analogous to fibrocystic disease of the breast.
  • Recognition of this benign entity is important since the differential diagnosis includes other more common benign and malignant salivary gland neoplasms, particularly mucoepidermoid carcinoma and tumors with cystic and oncocytic features.
  • Here we describe the fine-needle aspiration biopsy findings in a case of SPA of the parotid gland in an 84-year-old woman.
  • Occasional markedly vacuolated cells were present as well as many cells with apocrine change manifested by well-defined apical snouting.
  • Familiarity with the cytomorphologic features of SPA, including its characteristic apocrine changes, is important for distinguishing it from other more clinically significant salivary gland lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580340.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Shimato S, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Hasegawa Y, Hyodo I, Nagasaka T, Yoshida J: Brain metastases from apocrine carcinoma of the scalp: case report. J Neurooncol; 2006 May;77(3):285-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from apocrine carcinoma of the scalp: case report.
  • Apocrine carcinoma is an extremely rare malignant neoplasm that occurs most frequently in the axilla.
  • However, a literature search did not reveal any report describing the detailed clinical course of brain metastases from apocrine carcinoma.
  • We report a case of a 54-year-old male who suffered from multiple brain metastases from apocrine carcinoma that had originated in the scalp 6 years before.
  • To our knowledge this is the first reported case of metastatic brain tumor from apocrine carcinoma.
  • [MeSH-major] Apocrine Glands / pathology. Brain Neoplasms / secondary. Carcinoma / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314948.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Fulciniti F, Losito NS, Ionna F, Longo F, Aversa C, Botti G, Foschini MP: Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn Cytopathol; 2010 May;38(5):368-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation.
  • In line with numerous other pathological analogies between breast and salivary gland lesions, SPA shares with fibrocystic disease of the breast many histopathological features, i.e., fibrosis, oncocytic (apocrine) changes, hyperplasia of ductal and acinar epithelium, cystic dilation of ducts, and, often, atypical epithelial changes.
  • In this article, we introduce a new case occurring in the parotid gland of a 57-year-old male showing atypical epithelial hyperplasia and low-grade in situ mucoepidermoid carcinoma.
  • The spectrum of pathological lesions entering differential diagnosis comprised sebaceous adenoma, Warthin's tumors with presence of sebaceous remnants, and low-grade mucoepidermoid carcinoma.
  • Histopathological examination disclosed SCA with intraductal neoplastic transformation resembling noninvasive low-grade mucoepidermoid carcinoma.
  • The cytological diagnosis of SPA should be entertained whenever a polymorphous picture is found on FNC samples comprising oncocytic/apocrine changes, sebaceous cells, cystic background, and epithelial hyperplasia with low-grade cytological atypias.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology. Cysts / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937766.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K: Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J; 2008 Mar-Apr;14(2):164-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients.
  • Apocrine carcinoma is a rare, unique, and morphologically distinctive type of invasive ductal carcinoma (IDC).
  • The features of invasive apocrine carcinoma (IAC) and their possible prognostic implications have not been fully investigated.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Aged. Apocrine Glands / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Receptors, Estrogen. Receptors, Progesterone. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248561.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


41. Grin A, Colgan T, Laframboise S, Shaw P, Ghazarian D: "Pagetoid" eccrine carcinoma of the vulva: report of an unusual case with review of the literature. J Low Genit Tract Dis; 2008 Apr;12(2):134-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Pagetoid" eccrine carcinoma of the vulva: report of an unusual case with review of the literature.
  • Sweat gland carcinoma of the vulva is rare and may be classified as being of eccrine, apocrine, or mixed origin.
  • Most reported cases of vulvar sweat gland carcinomas associated with extramammary Paget disease describe a tumor of apocrine origin.
  • We report a case of a vulvar sweat gland carcinoma of eccrine origin associated with Pagetoid extension.
  • To our knowledge, this is the second case of vulvar sweat gland carcinoma of eccrine origin associated with extramammary Paget disease.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Sweat Gland Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369309.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Barré C, Lorenzato M, Bourdat B, Quéreux C, Durlach A: [Vulvar invasive squamous cell carcinoma and hidradenoma papilliferum. Case report]. Gynecol Obstet Fertil; 2007 Sep;35(9):776-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vulvar invasive squamous cell carcinoma and hidradenoma papilliferum. Case report].
  • We report a case of a vulvar invasive squamous cell carcinoma associated to a benign tumor with apocrine differenciation, the hidradenoma papilliferum, infiltrated by the carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Vulvar Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766164.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, Morgenfeld E, Rivarola E, Gil Deza E, Gercovich FG: 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast; 2005 Feb;14(1):3-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity?
  • Invasive apocrine carcinoma (IAC) of the breast has a similar prognosis to infiltrating ductal carcinoma not otherwise specified (IDC-NOS).
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Apocrine Glands. Case-Control Studies. Female. Humans. Middle Aged. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Breast. 2005 Feb;14(1):1-2 [15695073.001]
  • (PMID = 15695074.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


44. Grewal NS, Wan DC, Roostaeian J, Rubayi SR: Marjolin ulcer in hidradenitis suppurativa: case reports. Ann Plast Surg; 2010 Mar;64(3):315-7
MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidradenitis suppurativa is a chronic, recurrent, inflammatory disease of apocrine gland-bearing skin areas.
  • A rare complication is the development of squamous cell carcinoma, known as Marjolin ulcer.
  • We report 3 cases in which squamous cell carcinoma developed despite medical treatments and local excisions.
  • Because of the poor prognosis associated with squamous cell carcinoma, we advocate wide excision of hidradenitis suppurativa lesions when other treatments have failed.
  • [MeSH-major] Apocrine Glands / pathology. Apocrine Glands / surgery. Carcinoma, Squamous Cell. Hidradenitis Suppurativa. Sweat Gland Neoplasms. Ulcer / pathology

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179481.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ishida M, Katsura K, Nagata A, Kijima K, Kushima R, Okabe H: [A case of primary mucinous carcinoma with endocrine differentiation of the skin]. Rinsho Byori; 2008 Jun;56(6):455-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary mucinous carcinoma with endocrine differentiation of the skin].
  • Primary mucinous carcinoma of the skin (MCS) is a rare skin appendage tumor and only a few cases of MCS with endocrine differentiation have been reported.
  • This tumor did not accompany carcinoma in situ or invasive non-mucinous carcinoma and was difficult to differentiate from metastatic mucinous carcinoma of the skin.
  • MCS resembles mammary mucinous carcinoma not only in morphological appearance but also in immunohistochemical phenotypes, such as positive immunoreactivity to gross cystic disease protein fluid-15, MUC2, MUC6, estrogen receptor and progesterone receptor.
  • It is presumed that MCS is derived from the apocrine gland, which is closely related to the mammary gland.
  • Although endocrine differentiation is not uncommon in pure mucinous carcinoma of the breast, there have been only a few reports published on endocrine differentiation in MCS.
  • To clarify the difference and/or similarity between mucinous carcinoma of the breast and MCS, immunohistochemical and cytogenetic analyses of additional cases of MCS are required.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646630.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K, Sakamoto G: Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS; 2008 Oct;116(10):923-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast.
  • Apocrine carcinoma of the breast, which frequently expresses oestrogen receptor-beta (ER-beta) in the absence of ER-alpha and only infrequently is treated endocrinologically, gives an opportunity to investigate the clinicopathological role of ER-beta in breast cancer independent of ER-alpha expression or tamoxifen treatment.
  • Here we aimed to clarify the clinicopathological importance of ER-beta1 and ER-betacx (ER-beta2) in apocrine carcinomas, immunohistochemically examining expressions of ER-beta1 and ER-betacx in 47 apocrine carcinomas.
  • ER-beta1 positivity was also associated with favorable clinical outcome in 24 so-called triple-negative (ER-alpha-negative/PR-negative/HER2-negative) apocrine carcinomas.
  • ER-beta1 itself, independent of ER-alpha expression and tamoxifen treatment, seems to have a tumor-suppressive effect, at least in apocrine carcinomas.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / mortality. Carcinoma, Ductal, Breast / mortality. Estrogen Receptor beta / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132986.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; 0 / Protein Isoforms
  •  go-up   go-down


47. Rütten A, Kutzner H, Mentzel T, Hantschke M, Eckert F, Angulo J, Rodríguez Peralto JL, Requena L: Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm. J Am Acad Dermatol; 2009 Oct;61(4):644-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm.
  • BACKGROUND: Cribriform carcinoma is the histopathologic variant of cutaneous apocrine carcinoma characterized by interconnected solid aggregations of neoplastic cells that are punctuated by small round spaces.
  • METHODS: Twenty-six cases of primary cutaneous cribriform apocrine carcinoma were clinically, histopathologically, and immunohistochemically studied.
  • CONCLUSIONS: Primary cutaneous cribriform apocrine carcinoma is a distinctive but little-known variant of cutaneous apocrine carcinoma.
  • [MeSH-minor] Adult. Aged. Apocrine Glands / pathology. Biopsy. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cytoplasm / pathology. Cytoplasm / ultrastructure. Diagnosis, Differential. Epithelial Cells / pathology. Epithelial Cells / ultrastructure. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron. Microvilli / pathology. Microvilli / ultrastructure. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2011 Mar;64(3):599-601 [21315957.001]
  • (PMID = 19751882.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Kazakov DV, Calonje E, Rütten A, Glatz K, Michal M: Cutaneous sebaceous neoplasms with a focal glandular pattern (seboapocrine lesions): a clinicopathological study of three cases. Am J Dermatopathol; 2007 Aug;29(4):359-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presented here are three cutaneous sebaceous tumors (one carcinoma and two sebaceomas), each demonstrating a focal glandular pattern representing apocrine differentiation.
  • In both sebaceomas, at least a portion of the glands had a peripheral small-cell layer that appeared similar to the basal/myoepithelial cells of normal eccrine and apocrine ducts.
  • The descriptive terms seboapocrine carcinoma or seboapocrine sebaceoma are proposed for such lesions.
  • These tumors may be viewed as rare histopathological variants of sebaceous carcinoma and sebaceoma, with a second type of differentiation along the lines of the folliculosebaceous-apocrine unit.
  • [MeSH-major] Apocrine Glands / pathology. Scalp / pathology. Sebaceous Gland Neoplasms / pathology. Sebum
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Female. Follow-Up Studies. Humans. Hyperplasia. Male. Myocytes, Smooth Muscle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667168.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G: Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS; 2006 Oct;114(10):712-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
  • Gross cystic disease fluid protein-15 (GCDFP-15) is a commonly used apocrine marker; however, its expression was recently found to decrease in infiltrating, larger, or metastasizing apocrine carcinomas of the breast.
  • In the breast, monoclonal antibody (MAb) B72.3 has been reported to be useful as an apocrine marker although it is used for that purpose much less frequently than GCDFP-15.
  • In the search for a more consistent apocrine marker, immunoreactivity for MAb B72.3 was examined in apocrine carcinomas at different stages and compared with GCDFP-15.
  • 47 of 51 apocrine carcinomas (92%) and 9 of 62 ordinary carcinomas (15%) were MAb B72.3 positive, while 39 of 51 apocrine carcinomas (76%) and 13 of 62 ordinary carcinomas (21%) were GCDFP-15 positive.
  • The combined usage of MAb B72.3 with GCDFP-15 was useful to confirm the diagnosis of apocrine carcinoma, especially for advanced tumors, with only two cases being negative for both MAb B72.3 and GCDFP-15.
  • Whether these two cases should be differentiated from ordinary apocrine carcinomas remains to be investigated.
  • [MeSH-major] Apocrine Glands / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / secondary. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / secondary. Carrier Proteins / metabolism. Glycoproteins / metabolism. Immunohistochemistry / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004974.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  •  go-up   go-down


50. Kazakov DV, Magro G, Kutzner H, Spagnolo DV, Yang Y, Zaspa O, Mukensnabl P, Michal M: Spiradenoma and spiradenocylindroma with an adenomatous or atypical adenomatous component: a clinicopathological study of 6 cases. Am J Dermatopathol; 2008 Oct;30(5):436-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1 case, apocrine secretion was evident in the glandular part of the lesion.
  • As this alteration was limited and fairly well circumscribed within the tumor bulk, we regard it as an "atypical adenomatous component," but we cannot exclude the possibility that this may represent an incipient apocrine carcinoma, despite uneventful follow-up.
  • [MeSH-major] Adenoma / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Diagnosis, Differential. Female. Humans. Keratin-14 / metabolism. Male. Middle Aged. Myoepithelioma / diagnosis. Myoepithelioma / metabolism. Myoepithelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806484.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-14
  •  go-up   go-down


51. Puri PK, Galan A, Glusac EJ, Cowper SE: Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm. J Cutan Pathol; 2008 Jan;35(1):54-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 53-year-old male man presented with a neoplasm on the vertex of the scalp, clinically resembling a pigmented basal cell carcinoma.
  • RESULTS: A shave biopsy was suggestive of an apocrine poroma, however, a metastatic carcinoma could not be excluded.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Carcinoid Tumor / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095995.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Kazakov DV, Bisceglia M, Calonje E, Hantschke M, Kutzner H, Mentzel T, Michal M, Mukensnabl P, Spagnolo DV, Rütten A, Rose C, Urso C, Vazmitel M, Zelger B: Tubular adenoma and syringocystadenoma papilliferum: a reappraisal of their relationship. An interobserver study of a series, by a panel of dermatopathologists. Am J Dermatopathol; 2007 Jun;29(3):256-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TA has been recently suggested to represent a carcinoma.
  • Four observers blindly assessed 67 cases of TA, SCAP, and their lookalikes (poroma, apocrine adenoma, apocrine carcinoma; all lesions focally featuring a pseudopapillary pattern), and classified the lesions into one of four categories:.
  • All observers agreed that the lesions were benign; the only apocrine carcinoma included was recognized as such by all observers.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Cystadenoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sweat Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Syringocystadenoma papilliferum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519623.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


53. Talmant JC, Bruant-Rodier C, Nunziata AC, Rodier JF, Wilk A: [Squamous cell carcinoma arising in Verneuil's disease: two cases and literature review]. Ann Chir Plast Esthet; 2006 Feb;51(1):82-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma arising in Verneuil's disease: two cases and literature review].
  • Verneuil's disease (hidradenitis suppurativa) is a chronic inflammatory, suppurating, fistulizing and scar-producing disease of apocrine gland-bearing skin.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Hidradenitis / complications. Skin Neoplasms / complications. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488526.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 29
  •  go-up   go-down


54. Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M: Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci; 2007;6(1):21-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpreted images were evaluated for sensitivity, false negative rate (FN), sensitivity by pT, and sensitivity by background density of the mammary gland.
  • Sensitivities by background density of mammary gland were: fatty/scattered fibroglandular tissue, 95% (20/21) and heterogeneous fibroglandular tissue/mostly fibroglandular tissue, 98% (48/49).
  • Two cases, an intraductal and an apocrine carcinoma, were incorrectly diagnosed by MR imaging.
  • Precise diagnosis of breast cancer is possible with combined DWI and STIR, even in non-contrast MR imaging, regardless of the diameter or background density of mammary gland.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510539.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


55. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR: CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer; 2006;6:48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The aim of our study was to assess, by Methylation-Specific Polymerase Chain Reaction (MSP), the methylation pattern of the CDH1 gene and its possible correlation with the expression of E-cadherin and other standard immunohistochemical parameters (Her-2, ER, PgR, p53, and K-67) in a series of 79 primary breast cancers (71 infiltrating ductal, 5 infiltrating lobular, 1 metaplastic, 1 apocrine, and 1 papillary carcinoma).
  • RESULTS: CDH1 hypermethylation was observed in 72% of the cases including 52/71 ductal, 4/5 lobular carcinomas and 1 apocrine carcinoma.
  • [MeSH-major] Breast Neoplasms / genetics. Cadherins / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / genetics. Genes, Tumor Suppressor. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):115-27 [11446343.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):441-51 [12013533.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3382-6 [12067979.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):69-76 [12446956.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):349-51 [12478484.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3413-7 [12960130.001]
  • [Cites] Adv Anat Pathol. 2003 Sep;10(5):278-90 [12973049.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1811-5 [14534701.001]
  • [Cites] Mech Ageing Dev. 2003 Dec;124(10-12):989-98 [14659588.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):306-19 [14673164.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):697-704 [15178462.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):154-60 [15221598.001]
  • [Cites] Oncologist. 2004;9(4):361-77 [15266090.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1187-97 [15313416.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5349-54 [15328171.001]
  • [Cites] Science. 1995 Jan 20;267(5196):386-9 [7824937.001]
  • [Cites] Biotechniques. 1994 Nov;17(5):914-21 [7840973.001]
  • [Cites] J Biol Chem. 1996 Jan 5;271(1):595-602 [8550625.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1919-25 [8934538.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):185-91 [9219000.001]
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Int J Oncol. 1998 Jul;13(1):177-82 [9625819.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2515-9 [9635570.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):805-10 [9816234.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3855-60 [10463569.001]
  • [Cites] Hum Mutat. 1999;14(3):249-55 [10477433.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2727-32 [10644736.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(9):1098-106 [10854942.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4346-8 [10969774.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4243-8 [11106238.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):85-98 [11190811.001]
  • [Cites] Genomics. 2000 Dec 15;70(3):273-85 [11161777.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1171-7 [11221848.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):404-8 [11291078.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):39-44 [11343777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7202-6 [7913748.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2156-62 [15788661.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • (PMID = 16512896.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins
  • [Other-IDs] NLM/ PMC1523210
  •  go-up   go-down


56. Teschner M, Buhr T, Donnerstag F, Lenarz T, Majdani O: [Expansion of an ceruminous adenoma into the middle ear]. Laryngorhinootologie; 2006 Jun;85(6):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathohistology revealed a ceruminal gland adenoma.
  • They are a rare phenomenon and should be distinguished from middle ear adenomas, pleomorph ceruminal gland adenomas, ceruminal gland adenocarcinomas and cylindromas of the ceruminal glands.
  • Despite its rare occurrence, a ceruminal gland adenoma must be taken into consideration in the differential diagnosis of individual cholesteatoma cases.
  • [MeSH-major] Adenoma / diagnosis. Apocrine Glands / pathology. Carcinoma, Squamous Cell / diagnosis. Cerumen. Ear Canal / pathology. Ear Neoplasms / diagnosis. Ear, Middle / pathology. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770841.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Pornpanich K, Chindasub P: Eyelid tumors in Siriraj Hospital from 2000-2004. J Med Assoc Thai; 2005 Nov;88 Suppl 9:S11-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These 32 malignant eyelid tumors included 13 sebaceous gland carcinomas, 12 basal cell carcinomas, 3 malignant melanomas, 2 squamous cell carcinomas, 1 apocrine adenocarcinoma and 1 metastatic carcinoma.
  • Sebaceous gland carcinoma was the most common eyelid tumor found in their present study that was consistent with other studies from Asian countries.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Eyelid Neoplasms / epidemiology. Sebaceous Gland Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681045.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


58. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol; 2008 Apr;129(4):563-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH).
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / economics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cost-Benefit Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence / economics. In Situ Hybridization, Fluorescence / methods. Middle Aged. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology. Tissue Array Analysis / economics. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343783.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


59. Leeborg N, Thompson M, Rossmiller S, Gross N, White C, Gatter K: Diagnostic pitfalls in syringocystadenocarcinoma papilliferum: case report and review of the literature. Arch Pathol Lab Med; 2010 Aug;134(8):1205-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 86-year-old woman presented with a neoplasm on the neck, and the intralesional heterogeneity typical of these neoplasms led to an initial diagnosis on needle biopsy favoring squamous cell carcinoma.
  • Fortuitous sectioning revealed a focal connection to the skin surface with evidence of apocrine differentiation allowing final diagnosis as syringocystadenocarcinoma papilliferum.
  • We describe our findings and diagnostic pitfalls to help pathologists encountering this unusual apocrine neoplasm.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Sweat Gland Neoplasms / diagnosis. Syringoma / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / diagnosis. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Keratins / metabolism. Membrane Proteins / metabolism. Neoplasm Invasiveness. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20670144.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


60. Fahim L, Weinreb I, Alexander C, Perez Ordoñez B: Epithelial proliferation in small ducts of salivary cystadenoma resembling atypical ductal hyperplasia of breast. Head Neck Pathol; 2008 Sep;2(3):213-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salivary gland cystadenomas are cystic neoplasms with diverse architecture and cytology.
  • The epithelium of the larger cysts was composed of flat, cuboidal, columnar, and apocrine-like cells.
  • The smaller cysts and ducts had apocrine-like cells forming secondary glandular lumens.
  • Nuclear pleomorphism and hyperchromasia was seen in the apocrine-like cells.
  • Recognition of a prominent intraductal epithelial component in cystadenomas is important to avoid a misdiagnosis of cystadenocarcinoma or low-grade salivary duct carcinoma.
  • Cystadenomas join the list of salivary gland lesions with microscopic similarities to primary lesions of the breast.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / pathology. Cystadenoma / pathology. Salivary Ducts / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Hyperplasia. Keratin-19 / metabolism. Keratin-7 / metabolism. Male. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1440-7 [8944036.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):291-5 [10656742.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):e28-33 [18155598.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] Cancer. 1971 Mar;27(3):643-50 [5549498.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33 [2845326.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):161-70 [8554105.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):958-67 [8780532.001]
  • [Cites] Histopathology. 1997 Aug;31(2):185-8 [9279572.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jul;122(7):644-9 [9674547.001]
  • [Cites] J Oral Pathol Med. 1999 Jul;28(6):282-6 [10426203.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):154-64 [16434888.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):1014-21 [16861974.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):465-8 [11097376.001]
  • (PMID = 20614317.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-19; 0 / Keratin-7; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC2807557
  • [Keywords] NOTNLM ; Cystadenocarcinoma / Cystadenoma / Low-grade salivary duct carcinoma / Salivary glands
  •  go-up   go-down


61. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F: Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol; 2009 Jun;3(3):220-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
  • Invasive apocrine carcinomas (IACs), as defined by morphological features, correspond to 0.3-4% of all invasive ductal carcinomas (IDC), and despite the fact that they are histologically distinct from other breast lesions there are currently no standard molecular criteria available for their diagnosis and no unequivocal information as to their prognosis.
  • In an effort to address these concerns we have been using protein expression profiling technologies in combination with mass spectrometry and immunohistochemistry (IHC) to discover specific biomarkers that could allow us to molecularly characterize these lesions as well as to dissect some of the steps in the processes underlying breast apocrine metaplasia and development of precancerous apocrine lesions.
  • Establishing these apocrine-specific markers as best practice for the routine pathology evaluation of breast cancer, however, will require their validation in large cohorts of patients.
  • Towards this goal we have composed a panel of antibodies against components of an apocrine protein signature that includes probes against the apocrine-specific markers 15-prostaglandin dehydrogenase (15-PGDH), and acyl-CoA synthetase medium-chain family member 1 (ACSM1), in addition to a set of categorizing markers that are consistently expressed (AR, CD24) or not expressed (ERα, PgR, Bcl-2, and GATA-3) by apocrine metaplasia in benign breast lesions and apocrine sweat glands.
  • This panel was used to analyze a well-defined cohort consisting of 14 apocrine ductal carcinoma in situ (ADCIS), and 33 IACs diagnosed at the Cancer Institute Hospital, Tokyo between 1997 and 2001.
  • Samples were originally classified on the basis of cellular morphology with all cases having more than 90% of the tumour cells exhibiting cytological features typical of apocrine cells.
  • Using the expression of 15-PGDH and/or ACSM1 as the main criterion, but taking into account the expression of other markers, we were able to identify unambiguously 13 out of 14 ADCIS (92.9%) and 20 out of 33 (60.6%) IAC samples, respectively, as being of apocrine origin.
  • Our results demonstrate that IACs correspond to a distinct, even if heterogeneous, molecular subgroup of breast carcinomas that can be readily identified in an unbiased way using a combination of markers that recapitulate the phenotype of apocrine sweat glands (15-PGDH(+), ACSM1(+), AR(+), CD24(+), ERα(-), PgR(-), Bcl-2(-), and GATA-3(-)).
  • [MeSH-major] Apocrine Glands / metabolism. Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] Acta Oncol. 2006;45(6):643-61 [16938807.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Biotechnol Annu Rev. 2008;14:143-70 [18606362.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Pathol Biol (Paris). 2009 Jun;57(4):324-33 [19070972.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2799-805 [19008097.001]
  • [Cites] Tissue Eng Part C Methods. 2008 Sep;14(3):261-71 [18694322.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1006-12 [17105822.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Curr Opin Biotechnol. 1999 Feb;10(1):16-21 [10047502.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1854-63 [16002278.001]
  • [Cites] Breast J. 2008 Mar-Apr;14(2):164-8 [18248561.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1795-809 [18632593.001]
  • [Cites] Histopathology. 2007 Mar;50(4):425-33 [17448017.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):461-5 [12468268.001]
  • [Cites] Med Oncol. 1997 Jun;14(2):83-9 [9330267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):339-46 [16892043.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Histopathology. 2005 Aug;47(2):195-201 [16045781.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:343-72 [11701654.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402 [18950281.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Pathobiology. 2008;75(2):119-31 [18544967.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):42-54 [19383286.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):78-82 [19031117.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Pathology. 2009 Jan;41(1):68-76 [19089742.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):491-3 [16177777.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):223-8 [3356211.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jul;5(7):376-87 [18542103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7917-25 [16140963.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Breast. 2005 Feb;14(1):1-2 [15695073.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R30 [17504517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Int J Clin Pract. 2008 Mar;62(3):444-9 [18194278.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1041-55 [17129787.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):580-92 [17668425.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 19393583.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


62. Alex G: Apocrine adenocarcinoma of the nipple: a case report. Cases J; 2008;1(1):88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenocarcinoma of the nipple: a case report.
  • Apocrine adenocarcinomas are rare malignant skin adnexal tumours.
  • Apocrine carcinoma of the nipple is extremely rare and this case to the author's knowledge is only the third reported case worldwide and the first with associated ductal carcinoma in situ elsewhere in the breast.
  • A seventy one year old caucasian female presented to the breast clinic with a growth on her nipple which proved on histopathological analysis to be an apocrine carcinoma.
  • Recommended treatment for apocrine carcinoma includes surgery in the form of wide local excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Online J. 2008;14(6):5 [18713586.001]
  • [Cites] Acta Chir Belg. 2004 Aug;104(4):476-8 [15469170.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] J Neurooncol. 2006 May;77(3):285-9 [16314948.001]
  • (PMID = 18700029.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526981
  •  go-up   go-down


63. de Koning HD, Bovenschen HJ: Two adjacent nodules on the leg. Dermatol Online J; 2010;16(6):13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poroma is a rare benign neoplasm (derived from the intraepidermal part of the eccrine or apocrine duct), which may clinically mimic malignant tumors such as (amelanotic) malignant melanoma and porocarcinoma.
  • Histopathological examination is the key to the correct diagnosis, which is illustrated in the present case, in which a pigmented basal cell carcinoma and a poroma are in close proximity to each other.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Leg. Poroma / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20579468.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Peng Y, Ashfaq R, Ewing G, Leitch AM, Molberg KH: False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature. Am J Clin Pathol; 2008 Jul;130(1):21-7; quiz 146
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 3 cases of sentinel lymph nodes (SLNs) containing benign glandular inclusions (BGIs) in patients with breast carcinoma that were initially misdiagnosed as metastatic carcinoma.
  • The first case had an SLN with glandular elements adjacent to a squamous inclusion cyst, the second had an SLN with a single complex gland showing apocrine features, and the third had 2 SLNs, each containing rare glands lined by bland columnar cells and surrounded by thin, fibrous bands.
  • All glandular elements were distinctly different from the corresponding invasive carcinoma.
  • Our case series report indicates that comparison with the morphologic features of primary breast carcinoma and using immunohistochemical analysis for myoepithelial markers are important ancillary tools in distinguishing BGIs from metastatic carcinoma.
  • [MeSH-minor] Aged. Axilla. Carcinoma, Ductal, Breast / pathology. False Positive Reactions. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550466.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


65. Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, Hosoi T, Yoshimura N, Harada N, Younes M, Sakamoto G: Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology; 2007 Mar;50(4):425-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of oestrogen receptor-beta in apocrine carcinomas of the breast.
  • AIMS: Apocrine carcinoma of the breast seldom expresses oestrogen receptors (ER) or progesterone receptors (PR), but frequently expresses androgen receptors (AR).
  • Because of this unusual hormone receptor status, it has been suggested that oestrogens have a less important role in the pathogenesis of apocrine carcinoma.
  • The ER status of apocrine carcinoma has been studied for one kind of ER, the classic receptor now named ER-alpha; however, the status of ER-beta, a secondary oestrogen receptor, has not been examined systematically in apocrine carcinoma.
  • The aim was to study ER-beta status in apocrine carcinoma.
  • METHODS AND RESULTS: The expression of ER-beta was examined immunohistochemically in 48 apocrine carcinomas and compared with clinicopathological factors and ER-alpha, PR and AR status.
  • CONCLUSIONS: The significance of oestrogens in apocrine carcinoma should not be dismissed at present when the role of ER-beta remains to be determined.
  • Studying the action of oestrogen or antioestrogen in apocrine carcinoma may reveal a role for ER-beta independent of ER-alpha and raise the potential of hormonal therapy for these tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Estrogen Receptor alpha / biosynthesis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. RNA, Messenger / biosynthesis. Receptor, ErbB-2 / metabolism. Receptors, Androgen / biosynthesis. Receptors, Progesterone / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448017.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


66. Volmar KE, Cummings TJ, Wang WH, Creager AJ, Tyler DS, Xie HB: Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med; 2005 May;129(5):e113-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell hidradenoma is a benign skin appendage tumor that may mimic conventional-type renal cell carcinoma.
  • Histologically, clear cell hidradenoma contains small ductular lumens, focal apocrine and squamoid change, and a less prominent vascular pattern than renal cell carcinoma.
  • We report the rare case of a patient with renal cell carcinoma who underwent excision of an axillary clear cell hidradenoma, which was clinically suggestive of cutaneous metastatic disease.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859654.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Sarabi K, Khachemoune A: Hidrocystomas--a brief review. MedGenMed; 2006;8(3):57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidrocystomas, eccrine and apocrine, are rare cystic lesions that form benign tumors of the sweat glands.
  • We also review the effectiveness of experimental treatment methods and present information about associated syndromes and differential diagnosis, focusing especially on hidrocystomas' resemblance to basal cell carcinoma.
  • [MeSH-major] Hidrocystoma / pathology. Hidrocystoma / therapy. Sweat Gland Neoplasms / pathology. Sweat Gland Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2001 Apr;27(4):382-4 [11298711.001]
  • [Cites] Int J Dermatol. 2001 Feb;40(2):125-9 [11328394.001]
  • [Cites] Dermatol Surg. 2001 Oct;27(10):898-900 [11722530.001]
  • [Cites] Cleft Palate Craniofac J. 2002 Jul;39(4):469-73 [12071796.001]
  • [Cites] Int J Dermatol. 2002 May;41(5):295-7 [12100710.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 May;16(3):288-90 [12195577.001]
  • [Cites] J Dermatolog Treat. 2001 Jun;12(2):97-100 [12243666.001]
  • [Cites] Dermatol Surg. 2003 May;29(5):557-9 [12752528.001]
  • [Cites] Arch Dermatol. 2004 Feb;140(2):231-6 [14967804.001]
  • [Cites] Br J Dermatol. 1998 Sep;139(3):558-9 [9767322.001]
  • (PMID = 17406184.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  • [Other-IDs] NLM/ PMC1781304
  •  go-up   go-down


68. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.
  • We also found apocrine metaplasia, florid ductal hyperplasia, atypical hyperplasia, papilloma and LCIS associated with the malignant tumors.
  • The exceptions were represented by a case of fibroadenoma and the phyllodes tumor, with CD34 positivity and a focal acquisition of SMA; fibrocystic disease with associated apocrine metaplasia adjacent to a squamous carcinoma with loss of CD34 expression and focal acquisition of SMA.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


69. Liegl B, Horn LC, Moinfar F: Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Mod Pathol; 2005 Oct;18(10):1283-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary Paget's disease is almost exclusively associated with underlying invasive breast carcinoma or high-grade ductal carcinoma in situ (DCIS G3).
  • Extramammary Paget's disease arises in areas rich in apocrine glands and is suspected to have apocrine gland origin.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920545.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


70. Khalbuss WE: Cytomorphology of rare malignant tumors of the breast. Clin Lab Med; 2005 Dec;25(4):761-75, vii
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews cytomorphology of rare malignant tumors of the breast: squamous carcinoma, metaplastic carcinoma, adenoid cystic carcinoma, apocrine carcinoma, secretory carcinoma, lipid-rich carcinoma, and carcinoma with choriocarcinomatous features.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308090.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


71. Ogawa R, Akaishi S, Hyakusoku H: Differential and exclusive diagnosis of diseases that resemble keloids and hypertrophic scars. Ann Plast Surg; 2009 Jun;62(6):660-4
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous articles suggested the presence of various kinds of malignant tumors that resemble keloid or hypertrophic scar, including dermatofibrosarcoma protuberans, trichilemmal carcinoma, and keloidal basal cell carcinoma.
  • All tumors were benign: apocrine cystadenoma, adult-onset juvenile xanthogranuloma, mixed tumor, and chronic folliculitis.
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Adult. Cystadenoma / pathology. Diagnosis, Differential. Folliculitis / pathology. Humans. Male. Middle Aged. Sweat Gland Neoplasms / pathology. Xanthogranuloma, Juvenile / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461281.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Revuz J: Hidradenitis suppurativa. J Eur Acad Dermatol Venereol; 2009 Sep;23(9):985-98
MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidradenitis suppurativa is a chronic disease characterized by recurrent, painful, deep-seated, rounded nodules and abscesses of apocrine gland-bearing skin.
  • The primary event is a follicular occlusion with secondary inflammation, infection and destruction of the pilo-sebaceo-apocrine apparatus and extension to the adjacent sub-cutaneous tissue.
  • The main complications are arthropathy, carcinoma.

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • Genetics Home Reference. consumer health - hidradenitis suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682181.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


73. Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N, Sasano H: Androgens in human breast carcinoma. Med Mol Morphol; 2010 Jun;43(2):75-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens in human breast carcinoma.
  • Sex steroids play important roles in the development of human breast carcinoma.
  • Androgen receptor (AR) is expressed in a majority of breast carcinoma tissues.
  • However, the significance of androgen actions remains largely unclear in breast carcinoma, differing from estrogen actions.
  • Therefore, in this review, we summarized recent studies on androgens in breast carcinoma.
  • Concentration of a potent androgen, 5alpha-dihydrotestosterone (DHT), was significantly higher in breast carcinoma tissue than in plasma, and DHT is considered to be locally produced from circulating androstenedione by 17beta-hydroxysteroid dehydrogenase type 5 and 5alpha-reductase.
  • Androgens predominantly show antiproliferative effects in breast carcinoma cells, but association between AR status and the clinical outcome of the patient remains controversial, perhaps partly because AR status does not necessarily reflect androgenic action in breast carcinoma.
  • Recently, molecular apocrine breast carcinoma was identified by microarray analysis.
  • Molecular apocrine carcinoma was characterized by being estrogen receptor (ER) negative and AR positive and by being associated with increased androgen signaling and apocrine features.
  • Therefore, androgenic actions may also be involved in apocrine features in breast carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683693.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgens; 0 / Receptors, Estrogen; 08J2K08A3Y / Dihydrotestosterone; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


74. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol; 2008 Oct;216(2):141-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'.
  • We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling.
  • Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level.
  • When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Gene Expression Regulation, Neoplastic


75. Watanabe K, Nomura M, Hashimoto Y, Hanzawa M, Hoshi T: Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases. Diagn Cytopathol; 2007 May;35(5):296-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases.
  • Apocrine adenosis is a distinctive breast lesion, which can sometimes be misdiagnosed as malignant histologically.
  • We report fine-needle aspiration (FNA) cytology of three cases of apocrine adenosis.
  • Apocrine metaplasia with nuclear atypia mimicking apocrine carcinoma was prominent in one case, whereas one case lacked definite apocrine features.
  • Although FNA cytology of apocrine adenosis has the potential to be misinterpreted as malignant, the naked nuclei of background and less hyperchromatic nuclear features may be useful in distinguishing apocrine adenosis from carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427223.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Ohri A, Jetly D, Shukla K, Bansal R: Cytological grading of breast neoplasia and its correlation with histological grading. Indian J Pathol Microbiol; 2006 Apr;49(2):208-13
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our study we have analyzed 50 cases of breast carcinoma which included invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, stromal sarcoma, apocrine carcinoma, papillary carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933716.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


77. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M: Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol; 2005 Feb;27(1):27-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological survey revealed a plethora of benign adnexal neoplasms showing apocrine, follicular, and sebaceous differentiation occurring independently and conjointly.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Neoplasms, Multiple Primary / pathology. Neoplastic Syndromes, Hereditary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenoma, Sweat Gland / metabolism. Adenoma, Sweat Gland / pathology. Adenoma, Sweat Gland / surgery. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Diseases / surgery. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunoenzyme Techniques. Male. Sebaceous Glands / metabolism. Sebaceous Glands / pathology. Syndrome

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677973.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Tsunemi Y, Saeki H, Kikuchi K, Tamaki K, Sato S: Extramammary Paget's disease with intracytoplasmic lumen formation. J Dermatol; 2009 Dec;36(12):649-53
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramammary Paget's disease (EMPD) is regarded as a malignancy most likely derived from or differentiated into apocrine sweat duct and gland.
  • Signet ring cells and glandular formation support the traditional speculation that EMPD is derived from apocrine sweat gland and intracytoplasmic lumen formation may mimic the intrafollicular apocrine duct.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / diagnosis. Cytoplasm / pathology. Diagnosis, Differential. Genital Neoplasms, Male / diagnosis. Genital Neoplasms, Male / pathology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958450.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Obaidat NA, Alsaad KO, Ghazarian D: Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol; 2007 Feb;60(2):145-59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, many eccrine/apocrine lesions coexist within hamartomas or within lesions with composite/mixed differentiation.
  • In addition to the eccrine and apocrine glands, two other skin sweat glands have recently been described: the apoeccrine and the mammary-like glands of the anogenital area.
  • In this review (the second of two articles on skin adnexal neoplasms), common as well as important benign and malignant lesions of cutaneous sweat glands are described, and a summary for differentiating primary adnexal neoplasms from metastatic carcinoma is outlined, striving to maintain a common and acceptable terminology in this complex subject.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Adenoma, Sweat Gland / pathology. Carcinoma, Skin Appendage / pathology. Humans. Syringoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):829-32 [10690173.001]
  • [Cites] Am J Clin Pathol. 2000 Apr;113(4):572-5 [10761460.001]
  • [Cites] Am J Dermatopathol. 2000 Apr;22(2):97-103 [10770427.001]
  • [Cites] J Cutan Pathol. 2000 Apr;27(4):199-201 [10774942.001]
  • [Cites] Dermatology. 2000;200(3):250-3 [10828636.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):775-84 [10843279.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):83-9 [8721597.001]
  • [Cites] Am J Dermatopathol. 1996 Apr;18(2):124-36 [8739986.001]
  • [Cites] Mod Pathol. 1995 Dec;8(9):897-901 [8751328.001]
  • [Cites] J Cutan Pathol. 1996 Dec;23(6):566-70 [9001989.001]
  • [Cites] Pathol Res Pract. 1996 Nov;192(11):1135-9; discussion 1140-1 [9122033.001]
  • [Cites] Am J Dermatopathol. 1997 Apr;19(2):154-61 [9129700.001]
  • [Cites] J Cutan Pathol. 1997 Apr;24(4):256-60 [9138119.001]
  • [Cites] Am J Clin Pathol. 1997 Jul;108(1):6-12 [9208972.001]
  • [Cites] J Cutan Pathol. 1997 Jul;24(6):370-6 [9243365.001]
  • [Cites] Am J Dermatopathol. 1997 Aug;19(4):358-62 [9261470.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1178-87 [9331290.001]
  • [Cites] Am J Dermatopathol. 1998 Feb;20(1):35-40 [9504667.001]
  • [Cites] Ir J Med Sci. 1998 Jan-Mar;167(1):26-7 [9540295.001]
  • [Cites] Br J Dermatol. 1998 Apr;138(4):689-91 [9640381.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1125-31 [9737246.001]
  • [Cites] Acta Derm Venereol. 1998 Nov;78(6):460-2 [9833049.001]
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):131-5 [10199445.001]
  • [Cites] J Cutan Pathol. 1999 Apr;26(4):190-6 [10335896.001]
  • [Cites] J Cutan Pathol. 1999 May;26(5):232-41 [10408348.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):115-8 [10411423.001]
  • [Cites] Pathol Int. 1999 May;49(5):419-25 [10417685.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):431-5 [11417993.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2001 Mar;15(2):147-9 [11495523.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):689-92 [11533075.001]
  • [Cites] J Laryngol Otol. 2001 Aug;115(8):673-5 [11535157.001]
  • [Cites] J Am Acad Dermatol. 2001 Nov;45(5):755-9 [11606929.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2001 May;15(3):242-6 [11683289.001]
  • [Cites] Br J Dermatol. 2001 Oct;145(4):653-6 [11703297.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):591-4 [11958666.001]
  • [Cites] Hum Pathol. 2002 May;33(5):549-54 [12094382.001]
  • [Cites] Am J Dermatopathol. 2002 Oct;24(5):409-13 [12357203.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):936-45 [12410704.001]
  • [Cites] Cutis. 2003 Jan;71(1):49-52, 55 [12553630.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):453-5 [12637930.001]
  • [Cites] Dermatol Surg. 2000 Jun;26(6):580-3 [10848941.001]
  • [Cites] J Cutan Pathol. 2000 Aug;27(7):367-73 [10917164.001]
  • [Cites] Am J Dermatopathol. 2000 Dec;22(6):524-9 [11190445.001]
  • [Cites] J Cutan Pathol. 2001 Feb;28(2):101-4 [11168759.001]
  • [Cites] J Cutan Pathol. 2001 Feb;28(2):105-8 [11168760.001]
  • [Cites] Arch Pathol Lab Med. 2001 Apr;125(4):498-505 [11260623.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):625-7 [11260030.001]
  • [Cites] Am J Dermatopathol. 2001 Apr;23(2):87-9 [11285401.001]
  • [Cites] Am J Dermatopathol. 2001 Apr;23(2):154-7 [11285414.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):710-20 [11395548.001]
  • [Cites] Am J Dermatopathol. 2006 Apr;28(2):127-33 [16625074.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 May;20(5):608-10 [16684297.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] J Clin Pathol. 2007 Feb;60(2):129-44 [16882696.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):567-9 [17513517.001]
  • [Cites] Arch Pathol Lab Med. 1991 Dec;115(12):1249-54 [1662944.001]
  • [Cites] Am J Dermatopathol. 1992 Apr;14(2):149-54 [1566975.001]
  • [Cites] Am J Dermatopathol. 1992 Jun;14(3):245-52 [1510222.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1085-91 [1335210.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] J Cutan Pathol. 1993 Feb;20(1):40-3 [7682227.001]
  • [Cites] Am J Dermatopathol. 1993 Apr;15(2):150-5 [8494116.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1618-23 [7688655.001]
  • [Cites] Am J Dermatopathol. 1993 Oct;15(5):482-7 [8238787.001]
  • [Cites] Am J Dermatopathol. 1994 Feb;16(1):23-30 [8160927.001]
  • [Cites] Am J Dermatopathol. 1994 Feb;16(1):66-72 [7512801.001]
  • [Cites] Int J Gynecol Pathol. 1994 Apr;13(2):150-60 [8005737.001]
  • [Cites] Am J Dermatopathol. 1995 Jun;17(3):249-55 [8599433.001]
  • [Cites] Am J Dermatopathol. 1995 Oct;17(5):499-505 [8599457.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):73-6 [8721595.001]
  • [Cites] J Cutan Pathol. 2003 Mar;30(3):202-5 [12641781.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):790-2 [12828711.001]
  • [Cites] Dermatology. 2003;207(4):395-7 [14657634.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1224-31 [14681323.001]
  • [Cites] Eur J Dermatol. 2003 Sep-Oct;13(5):487-9 [14693496.001]
  • [Cites] J Dermatol. 2004 Jan;31(1):32-8 [14739501.001]
  • [Cites] J Cutan Pathol. 2004 Sep;31(8):561-4 [15268713.001]
  • [Cites] Am J Clin Pathol. 1977 Sep;68(3):397-9 [197847.001]
  • [Cites] Cancer. 1978 Feb;41(2):641-7 [204410.001]
  • [Cites] Br J Dermatol. 1980 Oct;103(4):443-8 [6254556.001]
  • [Cites] Arch Dermatol. 1984 Feb;120(2):231-3 [6696477.001]
  • [Cites] J Cutan Pathol. 1984 Oct;11(5):415-20 [6096424.001]
  • [Cites] Am J Surg Pathol. 1985 Sep;9(9):678-83 [2996375.001]
  • [Cites] Br J Dermatol. 1985 Nov;113(5):565-71 [2998432.001]
  • [Cites] J Hand Surg Br. 1986 Feb;11(1):139-43 [3007643.001]
  • [Cites] Am J Dermatopathol. 1986 Feb;8(1):64-72 [3518523.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Br J Dermatol. 1988 Apr;118(4):567-77 [2837268.001]
  • [Cites] Am J Dermatopathol. 1988 Feb;10(1):28-35 [2459984.001]
  • [Cites] J Cutan Pathol. 1989 Aug;16(4):230-6 [2551940.001]
  • [Cites] Am J Dermatopathol. 1991 Apr;13(2):162-8 [1709341.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):764-82 [15897743.001]
  • [Cites] Am J Dermatopathol. 2005 Jun;27(3):185-8 [15900119.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):757-61 [15976347.001]
  • [Cites] Histopathology. 2005 Aug;47(2):195-201 [16045781.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1283-8 [15920545.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S93-S126 [16446719.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):786-93 [10463481.001]
  • [Cites] Am J Dermatopathol. 2004 Dec;26(6):447-51 [15618924.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):50-4 [15660655.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] J Craniofac Surg. 2005 Jan;16(1):53-8 [15699645.001]
  • [Cites] Am J Dermatopathol. 2005 Apr;27(2):102-10 [15798433.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):263-8 [10642683.001]
  • (PMID = 16882695.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 110
  • [Other-IDs] NLM/ PMC1860616
  •  go-up   go-down


80. Kuroda N, Ohara M, Inoue K, Mizuno K, Fujishima N, Hamaguchi N, Lee GH: The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol; 2009 Jun;42(2):128-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.
  • Recently, the concept of basal-like carcinoma has been proposed.
  • However, there are only a few reports about the relationship between triple-negative cancer and basal-like carcinoma.
  • Eight tumors (4 metaplastic carcinomas, 2 invasive ductal carcinomas, 1 invasive papillary carcinoma, and 1 medullary carcinoma) were positive for more than three markers among cytokeratins 5, 14, and 17, and p63.
  • Three tumors (2 invasive ductal carcinomas and 1 apocrine carcinoma) were completely negative for all markers.
  • Finally, we conclude that the majority of triple-negative cancer may correspond to basal-like carcinoma, but the two entities are not identical.
  • The use of combination immunohistochemistry including cytokeratins 5, 14, and 17 and p63 may contribute to the detection of basal-like carcinoma.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Basal Cell / classification

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536621.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CKAP4 protein, human; 0 / Estrogen Receptor alpha; 0 / Keratin-14; 0 / Keratin-5; 0 / Membrane Proteins; 0 / Receptors, Progesterone
  •  go-up   go-down


81. Vaos G, Pierrakou P: Syringocystadenoma papilliferum: a rare breast tumor in a young boy. Pediatr Dev Pathol; 2006 Sep-Oct;9(5):381-3
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings support apocrine differentiation in this case.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Breast Neoplasms, Male / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / pathology. Child, Preschool. Diagnosis, Differential. Humans. Hyperplasia / pathology. Male. Papilloma / pathology

  • Genetic Alliance. consumer health - Syringocystadenoma papilliferum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16953682.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Kim ES, Lee DP, Lee MW, Choi JH, Moon KC, Koh JK: Cutaneous metastasis of uterine papillary serous carcinoma. Am J Dermatopathol; 2005 Oct;27(5):436-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine papillary serous carcinoma.
  • Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial adenocarcinoma that histologically and clinically resembles papillary serous carcinoma of the ovary.
  • This case demonstrates a very rare case of cutaneous metastasis of uterine papillary serous carcinoma.
  • A 54-year-old Korean female developed multiple pruritic skin nodules on the pubic area 13 months later after diagnosis of uterine papillary serous carcinoma.
  • A biopsy of the skin lesions showed papillary serous carcinoma, compatible with her primary tumor.
  • Without clinical history, it is difficult to distinguish other types of metastatic carcinoma to the skin and primary apocrine carcinoma of the skin from metastatic uterine papillary serous carcinoma.
  • Whereas uterine papillary serous carcinoma only rarely involves the skin, this entity should be included in the differential diagnosis of papillary adenocarcinoma in the skin.
  • [MeSH-minor] Bone Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Female. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Middle Aged. Neoplasms, Second Primary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148416.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Filipovski V, Banev S, Janevska V, Dukova B: Granular cell tumor of the breast: a case report and review of literature. Cases J; 2009;2:8551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main histological feature is granular cytoplasm of the tumor cells.From a clinical point of view there is a similarity between granular cell tumor and mammary carcinoma on mammography and ultrasound.
  • Pathohistologically, sometimes, differential diagnostic difficulties exist concerning apocrine carcinoma, histiocytic lesions and metastatic neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1992 Feb;116(2):206-8 [1733419.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):391-400 [6330972.001]
  • [Cites] Eur J Radiol. 1994 Nov;19(1):56-9 [7859762.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):709-11 [10782152.001]
  • [Cites] Cancer. 1953 Jul;6(4):786-9 [13059774.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 2):898-900 [2539575.001]
  • [Cites] Am J Clin Pathol. 1949 Jun;19(6):522-35 [18150636.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] South Med J. 1995 Nov;88(11):1146-8 [7481988.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):403-8 [8989543.001]
  • [Cites] South Med J. 1997 Nov;90(11):1149-51 [9386062.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):333-4 [12214737.001]
  • [Cites] AMA Arch Pathol. 1955 Dec;60(6):663-8 [13268207.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):302-3 [2830865.001]
  • (PMID = 19918386.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769456
  •  go-up   go-down


84. von Bomhard W, Goldschmidt MH, Shofer FS, Perl L, Rosenthal KL, Mauldin EA: Cutaneous neoplasms in pet rabbits: a retrospective study. Vet Pathol; 2007 Sep;44(5):579-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common nonviral epithelial tumors included trichoblastoma (59), squamous cell carcinoma (5), squamous papilloma (4), trichoepithelioma (3), and apocrine carcinoma (3).
  • [MeSH-minor] Adenoma / pathology. Adenoma / veterinary. Animals. Biopsy / veterinary. Carcinoma / pathology. Carcinoma / veterinary. Female. Hamartoma / pathology. Hamartoma / veterinary. Lipoma / pathology. Lipoma / veterinary. Lymphoma / pathology. Lymphoma / veterinary. Male. Melanoma / pathology. Melanoma / veterinary. Retrospective Studies. Sarcoma / pathology. Sarcoma / veterinary. Tumor Virus Infections / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846230.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Barbarino S, McCormick SA, Lauer SA, Milman T: Syringocystadenoma papilliferum of the eyelid. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):185-8
Genetic Alliance. consumer health - Syringocystadenoma papilliferum.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PubMed database was searched for reported cases of syringocystadenoma papilliferum of the eyelid (keywords: syringocystadenoma, eyelid, apocrine, eccrine).
  • Most cases had a preoperative diagnosis of basal cell carcinoma or cyst.
  • Nine lesions (64%) were associated with apocrine, eccrine, or sebaceous tumors or malformations.
  • This lesion is frequently clinically misdiagnosed as basal cell carcinoma or cyst.
  • [MeSH-major] Cystadenoma / pathology. Eyelid Neoplasms / pathology. Sweat Gland Neoplasms / pathology. Syringoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454927.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


86. Nariţa D, Raica M, Anghel A, Suciu C, Cîmpean A: Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol; 2005;46(1):41-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 24 selected breast tumors and 3 lymph nodes metastasis from patients with breast carcinoma.
  • The lesions with apocrine metaplasia were intense and constantly positive, the cystic dilated ducts and the areas with mastopathy were negative.
  • We discuss the results in terms of clinical implications of PSA immunoreactivity detection in mammary gland and other extra-prostatic sources.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286983.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


87. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • Apocrine carcinoma was also found very frequently in the TN group.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


88. Cecchi R, Pavesi M, Bartoli L, Brunetti L, Rapicano V: Perineal extramammary Paget disease responsive to topical imiquimod. J Dtsch Dermatol Ges; 2010 Jan;8(1):38-40
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramammary Paget disease (EMPD) is a rare neoplasm that arises in skin rich in apocrine glands, such as the axillae and anogenital region and usually affects the elderly.
  • In most cases, EMPD is an apocrine carcinoma in situ, but it can be associated with internal malignancy spreading to overlying skin.

  • Genetic Alliance. consumer health - Paget Disease.
  • Genetic Alliance. consumer health - Paget disease, extramammary.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096058.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


89. Ogiya A, Horii R, Osako T, Ito Y, Iwase T, Eishi Y, Akiyama F: Apocrine metaplasia of breast cancer: clinicopathological features and predicting response. Breast Cancer; 2010 Oct;17(4):290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine metaplasia of breast cancer: clinicopathological features and predicting response.
  • From our institutional neoadjuvant experience, apocrine carcinoma showed a high correlation with therapeutic effect against breast cancer.
  • We thus considered that apocrine metaplasia (AM) might represent a predictive marker for breast cancer.
  • CONCLUSIONS: Apocrine metaplasia appears to offer an effective predictive marker for anticancer therapy.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / chemistry. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789945.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / PIP protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


90. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F: Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett; 2006 May 22;580(12):2935-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
  • Breast cancer is a heterogeneous disease that encompasses a wide range of histopathological types including: invasive ductal carcinoma, lobular carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma, and apocrine carcinoma among others.
  • Pure apocrine carcinomas represent about 0.5% of all invasive breast cancers according to the Danish Breast Cancer Cooperative Group Registry, and despite the fact that they are morphologically distinct from other breast lesions, there are at present no standard molecular criteria available for their diagnosis.
  • In addition, the relationship between benign apocrine changes and breast carcinoma is unclear and has been a matter of discussion for many years.
  • Recent proteome expression profiling studies of breast apocrine macrocysts, normal breast tissue, and breast tumours have identified specific apocrine biomarkers [15-hydroxyprostaglandin dehydrogenase (15-PGDH) and hydroxymethylglutaryl coenzyme A reductase (HMG-CoA reductase)] present in early and advanced apocrine lesions.
  • These biomarkers in combination with proteins found to be characteristically upregulated in pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a protein expression signature distinctive for benign apocrine metaplasias and apocrine cystic lesions.
  • These studies have also presented compelling evidence for a direct link, through the expression of the prostaglandin degrading enzyme 15-PGDH, between early apocrine lesions and pure apocrine carcinomas.
  • Moreover, specific antibodies against the components of the expression signature have identified precursor lesions in the linear histological progression to apocrine carcinoma.
  • Finally, the identification of proteins that characterize the early stages of mammary apocrine differentiation such as 15-PGDH, HMG-CoA reductase, and cyclooxygenase 2 (COX-2) has opened a window of opportunity for pharmacological intervention, not only in a therapeutic manner but also in a chemopreventive setting.
  • Here we review published and recent results in the context of the current state of research on breast apocrine cancer.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631754.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 85
  •  go-up   go-down


91. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • SA with apocrine metaplasia, i.e. apocrine adenosis (AA), presents with a higher degree of atypical apocrine hyperplasia, and these lesions are believed to be precursors of apocrine carcinoma, in situ and invasive.
  • Analysis of 24 selected SA samples with apocrine metaplasia revealed non-obligate putative apocrine precancerous lesions that displayed some, or in same cases all the three markers associated with pure invasive apocrine carcinomas.
  • These studies also revealed p53 positive, non-apocrine putative precancerous lesions as well as novel phenotypes for ME and some luminal cells characterized by the expression of cytokeratin 15.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


92. Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G: Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology; 2005 Aug;47(2):195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
  • AIMS: Apocrine carcinoma of the breast is typically, though not always, positive for gross cystic disease fluid protein-15 (GCDFP-15).
  • In order to clarify the clinical significance of GCDFP-15 in apocrine carcinomas, GCDFP-15 expression was examined in apocrine carcinomas of different stages and compared with clinicopathological factors.
  • Apocrine lesions reportedly exhibit an unusual immunohistochemical status, expressing androgen receptors (AR) instead of oestrogen receptors (ER), progesterone receptors (PR), or bcl-2.
  • METHODS AND RESULTS: Fifty-two apocrine carcinomas were examined immunohistochemically.
  • CONCLUSIONS: GCDFP-15 positivity is transient and should not be considered a definitive marker of apocrine carcinomas.
  • Cases which have apocrine features but lack GCDFP-15 expression should rather be considered as advanced apocrine carcinomas.
  • ER/PR/bcl-2 negativity will sometimes be helpful to confirm the diagnosis of apocrine carcinoma, because it is more consistent than GCDFP-15/AR positivity.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carrier Proteins / biosynthesis. Glycoproteins / biosynthesis. Receptors, Androgen / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045781.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


93. Haji BE, Das DK, Al-Ayadhy B, Pathan SK, George SG, Mallik MK, Abdeen SM: Fine-needle aspiration cytologic features of four special types of breast cancers: mucinous, medullary, apocrine, and papillary. Diagn Cytopathol; 2007 Jul;35(7):408-16
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytologic features of four special types of breast cancers: mucinous, medullary, apocrine, and papillary.
  • In mucinous carcinoma, the frequency of signet ring cells (62.5%), and background pools of mucin (87.5%) were significantly higher than those of duct cell carcinoma (NOS), medullary carcinoma, apocrine carcinoma, and papillary carcinoma (P = 0.0408 to < 0.0001).
  • In medullary carcinomas, lymphomononuclear cell infiltration (100.0%) was observed in significantly higher number of cases than in papillary, mucinous, and apocrine types (P < 0.0001).
  • Further, moderate to marked nuclear pleomorphism (100.0%) and nuclear irregularity (77.8%) was significantly higher than those of mucinous carcinoma and papillary carcinoma (P = 0.0294 to <0.0003).
  • Abnormal apocrine cells and papillary formation, characterizing all the apocrine carcinomas and papillary carcinomas, respectively, were present in significantly lower number in other variants and in duct cell carcinoma (NOS) (P = 0.0002 to <0.0001).
  • Glycogen vacuoles (63.6%) were observed in a significantly higher number of papillary carcinoma as compared to duct cell carcinoma (NOS), apocrine, and medullary carcinomas (P = 0.0047 to 0.0022).
  • The significant parameters differentiating papillary carcinoma and benign papillary lesions were loose cohesive clusters (P = 0.001) and acinar formation by neoplastic cells (P = 0.0237).
  • Histopathology reports available in 36 cases, confirmed the cytodiagnosis of carcinoma in all 35 cases and the benign lesion in one case.
  • Cytological subtyping was confirmed in 13 of 16 special types of carcinomas and all the 15 duct cell carcinoma (NOS).
  • Thus, special and unusual variants of duct cell carcinomas like mucinous, medullary, apocrine, and papillary have specific cytomorphological features, which differentiate them from one another and from duct cell carcinoma (NOS).
  • However, differentiating features between papillary carcinoma and benign papillary lesions were very few in this study.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Apocrine Glands / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580344.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Elayat G, Selim AG, Wells CA: Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. Ann Diagn Pathol; 2010 Feb;14(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
  • Apocrine metaplasia (APM) is a common finding in the breast of postmenopausal women and is seen in a broad spectrum of lesions ranging from microscopic cysts to invasive apocrine carcinoma.
  • Apocrine metaplasia within sclerosing adenosis is known as apocrine adenosis (AA) and is considered a benign lesion of the breast.
  • Apocrine metaplasia and AA have been the subject of many studies; however, little is known about the dynamics of cell turnover in these lesions.
  • [MeSH-major] Apocrine Glands / pathology. Breast / pathology. Breast Neoplasms / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Division. Epithelium / metabolism. Epithelium / pathology. Female. Humans. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Metaplasia. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomerase / metabolism. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20123450.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-X Protein; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


95. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


96. Misago N, Aoki S, Shinoda Y, Toda S, Narisawa Y: Cartilaginous matrix-producing apocrine carcinoma of the skin. Br J Dermatol; 2010 Jul;163(1):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cartilaginous matrix-producing apocrine carcinoma of the skin.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331446.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


97. Gallerani E, Ciriolo M, Rossini C, Cavalli F: Axillary apocrine carcinoma with brain metastases. J Clin Oncol; 2007 Dec 10;25(35):5655-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / secondary. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apocrine Glands. Axilla. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neck. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Weinreb I, Bergfeld WF, Patel RM, Ghazarian DM: Apocrine carcinoma in situ of sweat duct origin. Am J Surg Pathol; 2009 Jan;33(1):155-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma in situ of sweat duct origin.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Skin Appendage / pathology. Scalp / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2008 May;32(5):682-90 [18347508.001]
  • (PMID = 18971780.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Tlemcani K, Levine D, Smith RV, Brandwein-Gensler M, Staffenberg DA, Garg MK, Shifteh K, Haigentz M Jr: Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J Clin Oncol; 2010 Aug 20;28(24):e412-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Scalp / pathology. Sweat Gland Neoplasms / drug therapy. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Alopecia / complications. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Drug Administration Schedule. Fatal Outcome. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Paclitaxel / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


100. Ruiz-Villaverde R, Martinez FE, Luque Barona RJ, Sanz Trelles A: Primary cutaneous cribriform apocrine carcinoma on a typical location. Eur J Dermatol; 2010 Nov-Dec;20(6):832-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform apocrine carcinoma on a typical location.
  • [MeSH-major] Facial Neoplasms / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923754.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down






Advertisement